CHRISTINA ALANIS: Open Payments
NPI 1851045736 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,692 in 66 payments from 20 companies in 2025. Trend: 2023 $2,782 · 2024 $1,549 · 2025 $1,692
Food & beverage: $1,692
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 9 | $365 |
| Novartis Pharmaceuticals Corporation | 16 | $337 |
| Amgen Inc. | 6 | $200 |
| Kestra Medical Technology Services, Inc. | 3 | $112 |
| Merck Sharp & Dohme LLC | 5 | $86 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $78 |
| Novo Nordisk Inc | 3 | $64 |
| Actelion Pharmaceuticals US, Inc. | 2 | $61 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $52 |
Products named: LEQVIO, AMVUTTRA, REPATHA, Assure WCD, VERQUVO, LifeVest, OPSUMIT, Kerendia.
Industry payments across TX — which companies pay providers there.
